Enpicom secures funding round to finalize igx platform development
Bioinformatics software engineering company ENPICOM has closed a series A investment round. BOM Brabant Ventures, Nextgen Ventures and Arches Capital have jointly invested 1.2 million euros to support the company’s repertoire sequencing data analysis platform. ENPICOM will use these proceeds to finalize development of its ImmunoGenomiX (IGX) platform and introduce it in the marketplace.
ENPICOM BV was founded in 2017 by Dr. Alvise Trevisan (CTO), Dr. Nicola Bonzanni (CSO) and Jos Lunenberg, MSc, MBA (CEO). Mid 2017 the company started the development of a unique platform to manage, store, analyze, visualize and interpret clone sequencing data from T and B cell receptor repertoires. ENPICOM is currently in the final stage of preparations for the global launch of the first full version of its ImmunoGenomiX (IGX) platform. This festive event will take place in Vienna at the 6th Immunotherapy of Cancer Conference (ITOC6) from April 11 to 13.
Dr. Bonzanni commented: “When studying immune system related diseases or developing drugs influencing this system, it is extremely important to be able to directly measure and closely monitor its status. Repertoire sequencing is a powerful way to analyze hundreds of thousands to millions of T or B cell receptors swiftly and in a cost-effective way.” “While there are different companies offering kits and service for this specific form of targeted sequencing, there is no commercial platform to manage the rapidly growing amounts of data generated in the lab in an intuitive, user-friendly way,” added Dr. Trevisan. He continued: “To get from data to powerful insights from this exciting technology, smart new analysis methods and rock-solid software were needed. We have built a team of experts, bringing together a wealth of knowledge and expertise in this field, to develop the IGX platform.”
“I am very pleased we have attracted this excellent syndicate of investors,” said CEO Lunenberg. “With the completion of this Series A financing, we are well funded to execute on our IGX development and market introduction programs.”
Quotes from the investors
Sjoerd van Gorp (BOM): “The ambitions of the ENPICOM team in the field of personalized immunotherapy fits perfectly with our investment goals. By providing innovative life sciences companies and healthcare providers with the tools to measure the status of the patients’ immune system we believe that ENPICOM can facilitate efficient drug development and ensure effective treatment for patients.”
Matthijs Blokhuis (NextGen Ventures): “The ambition of ENPICOM to personalize immunotherapy resonates extremely well with the objective of NextGen Ventures to provide meaningful results for patients and providers. An increased understanding of immune repertoire sequencing data significantly helps to improve outcomes in an efficient manner.”
Eric van der Maten (Arches Capital): “ENPICOM is a perfect example of what we look for in a portfolio company: a strong, highly skilled, motivated and dedicated team, that is showing the ability to combine innovative emerging technologies like data science, AI and medical science into an exhilarating and fast-growing Deep Tech company, eventually even with a real impact on society. We are very pleased to add ENPICOM to our investment portfolio”.
Source: ENPICOM
